ArriVent BioPharma, Inc.
AVBP Nasdaq
SEC CIK 1868279
Follow ArriVent BioPharma
Weekly email: filings, results
Revenue, last quarter
$5M
Net income
−$40.3M
−15.3% vs same quarter last year
EPS, diluted
−$0.81
+2.4% vs same quarter last year
Operating cash flow
−$40.7M
−13.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$166.3M |
| FY24 | −$80.5M |
| FY23 | −$69.3M |
| FY22 | - |